Stephen F. Mahoney

Director, President and CEO; President and CEO · 2 filings · Latest: Mar 3, 2026

Viridian Therapeutics, Inc.\DE

Ticker	Owner	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Filing
VRDN	Stephen F. Mahoney	President and CEO	Mar 3, 2026	Option Exercise	—	18,357	—	40,757	Mar 4 11:56 PM
VRDN	Mahoney Stephen F.	—	Mar 4, 2026	Proposed Sale	$30.19	7,408	$223.6K	—	Mar 4 9:10 PM